Point-of-care testing: what a $139 box really buys

Follow the $139 box through the budget

The opened CLIAwaived offer for ten Piccolo Comprehensive Metabolic discs is US$139 plus US$30 shipping/handling per item, checked October 16, 2026. That makes the listed pack US$169, or US$16.90 per disc if all ten produce usable patient results, before tax, controls and other costs. The offer requires a valid CLIA number; it is a US price anchor, not an export supply commitment.

Now change only the denominator. In an illustrative scenario where eight of those discs produce usable patient results, the same US$169 becomes US$21.13 per result. This is arithmetic, not an observed waste or failure rate. It shows why a small clinic should compare delivered packs and realistically usable quantities. MedicalRite's US$537.99 offer for 25 i-STAT CHEM8+ cartridges gives approximately US$21.52 each before additions, but the panels and seller terms differ and the page's availability statements conflict. These are separate budget examples, not evidence that one assay platform is cheaper for equivalent care.

Choose the result the service needs

An urgent blood-gas requirement points toward epoc or appropriate i-STAT cartridges. Routine chemistry panels point toward a different comparison that includes Piccolo. Start with analytes, sample types, intended patients and acceptable turnaround. Buying a broad analyzer to repeat work a nearby reliable laboratory already supplies may consume funds without closing a service gap.

epoc's room-temperature cards are useful when refrigeration is the obstacle, but their 15–30°C storage limit still requires control. A hot vehicle is not suitable merely because the cards are described as room-temperature products. Piccolo discs require 2–8°C storage. Account for those conditions during delivery and storage as well as on the testing day. For epoc, card calibration also precedes sample analysis, so post-sample timing does not describe the whole workflow.

Start a small clinic with the tests it can sustain

Treat hemoglobin, glucose and urine as distinct services with their own supplies and quality control. Hb 301's stated 10–40°C operation and cuvette-storage range gives it a tangible reason to lead a warm-site comparison. Hb 201+ can remain the economical choice where its 15–30°C limits fit and replenishment already works. Its stated three-month opened-vial stability also matters when use is intermittent.

For glucose, specify the professional multipatient setting and intended patient population before comparing meters. Xpress 2 offers simpler data handling; Inform II supports a more connected professional workflow. Include strips, controls, approved cleaning, identification and any base or network costs. A low retail-meter price does not establish an equivalent clinic setup.

Keep the October 5, 2026 Nova notice attached to the exact affected Gen 2.0 hospital-meter models: it describes a wrong-patient-result risk, shipment hold and a software remedy still being developed in that notice. Do not assume the remedy is complete or extend the action to every StatStrip variant. Model and software identification are buying facts, not administrative details.

Buy a reader when its workflow earns the hardware

CLINITEK Status+ is a defined new urine-reader option with specified Siemens strips and CLINITEST hCG compatibility. A functioning McKesson Consult 120 may deserve retention when its exact strips, controls and support remain available. Confirm the actual reader identity: the 121-120 guide and current reagent listings do not prove indefinite new-analyzer production or universal compatibility with U120 accessories.

A reader is not required for every added test. QuickVue hCG Urine provides a specific standalone option with regional kit numbers, 25-test packaging and 15–30°C storage; external controls are a separate supply item. Compare that complete workflow with reader-based testing at actual demand.

For HbA1c, compare how quickly a clinic can use an A1CNow+ professional pack with the continuing demand needed to justify DCA Vantage. A1CNow+'s 18–28°C operating limit can be decisive at a warm site. DCA's additional albumin/creatinine capability deserves funding when the service will use it, alongside the required assay-specific controls.

Fund the complete test pathway

Stool-test purchasing illustrates the final trap: Hemoccult ICT collection cards need matching test devices/buffer and controls, while SENSA uses a different slides-and-developer method. A cheap box of collection cards is not a complete testing system. The responsible program must choose the method and fund sample return, result review and follow-up.

Use the same discipline across the clinic: order enough usable stock to cover demand and planned controls, monitor expiry and temperature, and record repeats so the next purchase uses the service's own data. No comparative field-failure evidence establishes a universal best analyzer. The strongest budget choice is the supported workflow that produces the required results at a sustainable recurring cost.